Synopsis
Synopsis
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
Annual Reports
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-(diethylamino)-2-butynyl-alpha-cyclohexyl-alpha-hydroxybenzeneacetate
2. 4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate
3. Apo-oxybutynin
4. Contimin
5. Cystonorm
6. Cystrin
7. Ditropan
8. Dresplan
9. Dridase
10. Driptane
11. Gelnique
12. Gen-oxybutynin
13. Novo-oxybutynin
14. Nu-oxybutyn
15. Oxyb Abz
16. Oxybugamma
17. Oxybutin Holsten
18. Oxybuton
19. Oxybutynin
20. Oxybutynin Al
21. Oxybutynin Azu
22. Oxybutynin Heumann
23. Oxybutynin Hexal
24. Oxybutynin Hydrochloride
25. Oxybutynin Stada
26. Oxybutynin Von Ct
27. Oxybutynin-puren
28. Oxybutynin-ratiopharm
29. Oxymedin
30. Oxytrol
31. Pms-oxybutynin
32. Pollakisu
33. Renamel
34. Ryol
35. Spasmex Oxybutynin
36. Spasyt
37. Tavor
38. Zatur
1. Oxybutynin Hydrochloride
2. 1508-65-2
3. Oxybutynin Hcl
4. Tropax
5. Oxybutynin (chloride)
6. Ditropan Xl
7. Pollakisu
8. Mj 4309-1
9. L9f3d9renq
10. Nsc-759108
11. Alpha-phenylcyclohexaneglycolic Acid 4-(diethylamino)-2-butynyl Ester Hydrochloride
12. Mls000069688
13. 4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate Hydrochloride
14. Dridase
15. Smr000058490
16. Mj-4309-1
17. 4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate;hydrochloride
18. Oxybutynin Hydrochloride (jan)
19. 4-diethylamino-2-butynyl Phenyl(cyclohexyl)glycolate Hydrochloride
20. 4-(diethylamino)-2-butynyl Alpha-phenylcyclohexaneglycolate Hydrochloride
21. Gelnique
22. Oxibutinina Hydrochloride
23. Oxybutynin Hydrochloride [jan]
24. Chebi:7857
25. 4-diethylaminobut-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylethanoate Hydrochloride
26. Oxybutynin Chloride [usan]
27. Oxybutyninhydrochloride
28. Sr-01000000184
29. Einecs 216-139-7
30. Unii-l9f3d9renq
31. 4-(diethylamino)but-2-ynyl Cyclohexylphenylglycolate Hydrochloride
32. Oxybutynin Chloride [usan:usp]
33. Ditropan (tn)
34. Gelnique (tn)
35. Prestwick_621
36. Mfcd00072150
37. Oxybutynin-d11 Hcl
38. 4-(diethylamino)but-2-yn-1-yl Cyclohexyl(hydroxy)phenylacetate Hydrochloride
39. Opera_id_1330
40. Ncgc00016583-01
41. Oxybutynin (hydrochloride)
42. Oxybutynin Chloride (usp)
43. Cas-1508-65-2
44. Chembl1133
45. Dsstox_cid_25356
46. Dsstox_rid_80822
47. Dsstox_gsid_45356
48. Schembl25751
49. Mls001148211
50. Mls002222232
51. Regid_for_cid_91505
52. Dtxsid3045356
53. Hy-b0267a
54. (s)-4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate Hydrochloride
55. Hms1568j16
56. Pharmakon1600-01505399
57. (r,s) - Oxybutynin Hydrochloride
58. Oxybutynin Chloride [vandf]
59. Bcp12138
60. Oxybutynin Chloride-(phenyl-[d5])
61. Tox21_110507
62. Tox21_500923
63. Nsc759108
64. Oxybutynin Chloride [usp-rs]
65. Oxybutynin Hydrochloride [mi]
66. S3117
67. 4-(diethylamino)-2-butynyl (+-)-alpha-phenylcyclohexaneglycolate Hydrochloride
68. Akos015895349
69. Ccg-213420
70. H33o205
71. Ks-1377
72. Lp00923
73. Nc00580
74. Nsc 759108
75. Cyclohexaneglycolic Acid, Alpha-phenyl-, 4-(diethylamino)-2-butynyl Ester, Hydrochloride
76. Oxybutynin Hydrochloride [mart.]
77. Ncgc00094234-01
78. Ncgc00094234-02
79. Ncgc00261608-01
80. Oxybutynin Chloride [orange Book]
81. Oxybutynin Hydrochloride [who-dd]
82. Benzeneacetic Acid, Alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl Ester Hydrochloride
83. Benzeneacetic Acid, Alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl Ester Hydrochloride, (+-)-
84. Bo166187
85. Oxybutynin Chloride [usp Impurity]
86. Oxybutynin Chloride [usp Monograph]
87. Eu-0100923
88. Ft-0603563
89. Ft-0673411
90. Ft-0673412
91. O0451
92. Oxybutynin Chloride, >=98% (tlc), Powder
93. Sw196787-4
94. A51042
95. D00722
96. O 2881
97. Oxybutynin Hydrochloride [ep Monograph]
98. Oxybutynin Hydrochloride [usp Impurity]
99. A809082
100. J-008750
101. Sr-01000000184-2
102. Sr-01000000184-7
103. Q27107600
104. Oxybutynin Chloride, Meets Ep, Usp Testing Specifications
105. Oxybutynin Chloride, United States Pharmacopeia (usp) Reference Standard
106. Oxybutynin Hydrochloride, British Pharmacopoeia (bp) Reference Standard
107. Oxybutynin Hydrochloride, European Pharmacopoeia (ep) Reference Standard
108. 2-cyclohexyl-2-hydroxy-2-phenylacetic Acid 4-(diethylamino)but-2-ynyl Ester Hcl
109. 4-(diethylamino)-2-butynyl (+/-)-,alpha.-phenylcyclohexaneglycolate Hydrochloride
110. 4-(diethylamino)but-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate Hydrochloride
111. 4-diethylamino-2-butynylphenyl(cyclohexyl)glycolatehydrochloride;oxybutynin Hcl
112. Alpha-phenylcyclohexaneglycolic Acid 4-(diethylamino)-2-butynyl Ester, Hydrochloride
113. Benezeneactetic Acid, .alpha.-cyclohexyl-.alpha.-hydroxy-,4-(diethylamino-2-butunyl Ester Hydrochloride,(+/-)-
114. Benzeneacetic Acid, .alpha.-cyclohexyl-.alpha.-hydroxy-, 4-(diethylamino)-2-butynyl Ester Hydrochloride, (+/-)-
Molecular Weight | 393.9 g/mol |
---|---|
Molecular Formula | C22H32ClNO3 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 8 |
Exact Mass | 393.2070716 g/mol |
Monoisotopic Mass | 393.2070716 g/mol |
Topological Polar Surface Area | 49.8 Ų |
Heavy Atom Count | 27 |
Formal Charge | 0 |
Complexity | 490 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 8 | |
---|---|
Drug Name | Ditropan xl |
Drug Label | DITROPAN XL (oxybutynin chloride) is an antispasmodic, anticholinergic agent. Each DITROPAN XL Extended Release Tablet contains 5 mg, 10 mg, or 15 mg of oxybutynin chloride USP, formulated as a once-a-day controlled-release tablet for oral admini... |
Active Ingredient | Oxybutynin chloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | 5mg; 10mg; 15mg |
Market Status | Prescription |
Company | Janssen Pharms |
2 of 8 | |
---|---|
Drug Name | Gelnique |
PubMed Health | Oxybutynin (By mouth) |
Drug Classes | Urinary Antispasmodic |
Drug Label | Oxybutynin is an antispasmodic, antimuscarinic agent. GELNIQUE (oxybutynin chloride) is a clear and colorless hydroalcoholic gel containing 100 mg oxybutynin chloride per gram of gel. GELNIQUE is available in a 1 gram (1.14 mL) unit dose that contain... |
Active Ingredient | Oxybutynin chloride |
Dosage Form | Gel |
Route | Transdermal |
Strength | 10%(100mg/packet) |
Market Status | Prescription |
Company | Watson Labs |
3 of 8 | |
---|---|
Drug Name | Oxybutynin chloride |
Drug Label | Oxybutynin chloride tablets USP are a debossed, very pale blue, round, biconvex, scored tablet containing 5 mg of oxybutynin chloride, USP. Chemically, oxybutynin chloride is d,l (racemic) 4-diethylamino-2-butynyl phenylcyclohexylglycolate hydrochlor... |
Active Ingredient | Oxybutynin chloride |
Dosage Form | Tablet, extended release; Tablet; Syrup |
Route | Oral |
Strength | 15mg; 5mg; 10mg; 5mg/5ml |
Market Status | Prescription |
Company | Vintage Pharms; Impax Pharms; Mylan Pharms; Wockhardt; Silarx; Pharm Assoc; Teva Pharms Usa; Osmotica Pharm; Usl Pharma; Mylan |
4 of 8 | |
---|---|
Drug Name | Oxybutynin chloride |
PubMed Health | Oxybutynin |
Drug Classes | Urinary Antispasmodic |
Drug Label | Oxybutynin chloride tablets USP are a debossed, very pale blue, round, biconvex, scored tablet containing 5 mg of oxybutynin chloride, USP. Chemically, oxybutynin chloride is d,l (racemic) 4-diethylamino-2-butynyl phenylcyclohexylglycolate hydrochlor... |
Active Ingredient | Oxybutynin chloride |
Dosage Form | Tablet, extended release |
Route | oral |
Strength | 15 mg. |
Market Status | Prescription |
Company | Mylan Pharms |
5 of 8 | |
---|---|
Drug Name | Ditropan xl |
Drug Label | DITROPAN XL (oxybutynin chloride) is an antispasmodic, anticholinergic agent. Each DITROPAN XL Extended Release Tablet contains 5 mg, 10 mg, or 15 mg of oxybutynin chloride USP, formulated as a once-a-day controlled-release tablet for oral admini... |
Active Ingredient | Oxybutynin chloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | 5mg; 10mg; 15mg |
Market Status | Prescription |
Company | Janssen Pharms |
6 of 8 | |
---|---|
Drug Name | Gelnique |
PubMed Health | Oxybutynin (By mouth) |
Drug Classes | Urinary Antispasmodic |
Drug Label | Oxybutynin is an antispasmodic, antimuscarinic agent. GELNIQUE (oxybutynin chloride) is a clear and colorless hydroalcoholic gel containing 100 mg oxybutynin chloride per gram of gel. GELNIQUE is available in a 1 gram (1.14 mL) unit dose that contain... |
Active Ingredient | Oxybutynin chloride |
Dosage Form | Gel |
Route | Transdermal |
Strength | 10%(100mg/packet) |
Market Status | Prescription |
Company | Watson Labs |
7 of 8 | |
---|---|
Drug Name | Oxybutynin chloride |
Drug Label | Oxybutynin chloride tablets USP are a debossed, very pale blue, round, biconvex, scored tablet containing 5 mg of oxybutynin chloride, USP. Chemically, oxybutynin chloride is d,l (racemic) 4-diethylamino-2-butynyl phenylcyclohexylglycolate hydrochlor... |
Active Ingredient | Oxybutynin chloride |
Dosage Form | Tablet, extended release; Tablet; Syrup |
Route | Oral |
Strength | 15mg; 5mg; 10mg; 5mg/5ml |
Market Status | Prescription |
Company | Vintage Pharms; Impax Pharms; Mylan Pharms; Wockhardt; Silarx; Pharm Assoc; Teva Pharms Usa; Osmotica Pharm; Usl Pharma; Mylan |
8 of 8 | |
---|---|
Drug Name | Oxybutynin chloride |
PubMed Health | Oxybutynin |
Drug Classes | Urinary Antispasmodic |
Drug Label | Oxybutynin chloride tablets USP are a debossed, very pale blue, round, biconvex, scored tablet containing 5 mg of oxybutynin chloride, USP. Chemically, oxybutynin chloride is d,l (racemic) 4-diethylamino-2-butynyl phenylcyclohexylglycolate hydrochlor... |
Active Ingredient | Oxybutynin chloride |
Dosage Form | Tablet, extended release |
Route | oral |
Strength | 15 mg. |
Market Status | Prescription |
Company | Mylan Pharms |
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Parasympatholytics
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)
Urological Agents
Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ANALYTICAL
ABOUT THIS PAGE
48
PharmaCompass offers a list of Oxybutynin Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Oxybutynin Hydrochloride manufacturer or Oxybutynin Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Oxybutynin Hydrochloride manufacturer or Oxybutynin Hydrochloride supplier.
PharmaCompass also assists you with knowing the Oxybutynin Hydrochloride API Price utilized in the formulation of products. Oxybutynin Hydrochloride API Price is not always fixed or binding as the Oxybutynin Hydrochloride Price is obtained through a variety of data sources. The Oxybutynin Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A KS-1377 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of KS-1377, including repackagers and relabelers. The FDA regulates KS-1377 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. KS-1377 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of KS-1377 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A KS-1377 supplier is an individual or a company that provides KS-1377 active pharmaceutical ingredient (API) or KS-1377 finished formulations upon request. The KS-1377 suppliers may include KS-1377 API manufacturers, exporters, distributors and traders.
click here to find a list of KS-1377 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A KS-1377 DMF (Drug Master File) is a document detailing the whole manufacturing process of KS-1377 active pharmaceutical ingredient (API) in detail. Different forms of KS-1377 DMFs exist exist since differing nations have different regulations, such as KS-1377 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A KS-1377 DMF submitted to regulatory agencies in the US is known as a USDMF. KS-1377 USDMF includes data on KS-1377's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The KS-1377 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of KS-1377 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The KS-1377 Drug Master File in Japan (KS-1377 JDMF) empowers KS-1377 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the KS-1377 JDMF during the approval evaluation for pharmaceutical products. At the time of KS-1377 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of KS-1377 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a KS-1377 Drug Master File in Korea (KS-1377 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of KS-1377. The MFDS reviews the KS-1377 KDMF as part of the drug registration process and uses the information provided in the KS-1377 KDMF to evaluate the safety and efficacy of the drug.
After submitting a KS-1377 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their KS-1377 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of KS-1377 suppliers with KDMF on PharmaCompass.
A KS-1377 CEP of the European Pharmacopoeia monograph is often referred to as a KS-1377 Certificate of Suitability (COS). The purpose of a KS-1377 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of KS-1377 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of KS-1377 to their clients by showing that a KS-1377 CEP has been issued for it. The manufacturer submits a KS-1377 CEP (COS) as part of the market authorization procedure, and it takes on the role of a KS-1377 CEP holder for the record. Additionally, the data presented in the KS-1377 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the KS-1377 DMF.
A KS-1377 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. KS-1377 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of KS-1377 suppliers with CEP (COS) on PharmaCompass.
A KS-1377 written confirmation (KS-1377 WC) is an official document issued by a regulatory agency to a KS-1377 manufacturer, verifying that the manufacturing facility of a KS-1377 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting KS-1377 APIs or KS-1377 finished pharmaceutical products to another nation, regulatory agencies frequently require a KS-1377 WC (written confirmation) as part of the regulatory process.
click here to find a list of KS-1377 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing KS-1377 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for KS-1377 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture KS-1377 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain KS-1377 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a KS-1377 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of KS-1377 suppliers with NDC on PharmaCompass.
KS-1377 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of KS-1377 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right KS-1377 GMP manufacturer or KS-1377 GMP API supplier for your needs.
A KS-1377 CoA (Certificate of Analysis) is a formal document that attests to KS-1377's compliance with KS-1377 specifications and serves as a tool for batch-level quality control.
KS-1377 CoA mostly includes findings from lab analyses of a specific batch. For each KS-1377 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
KS-1377 may be tested according to a variety of international standards, such as European Pharmacopoeia (KS-1377 EP), KS-1377 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (KS-1377 USP).